Boehringer Ingelheim GmbH’s IL-36 inhibitor Spevigo has impressed in a pivotal trial for generalized pustular psoriasis (GPP) flare prevention with plans in place for regulatory filings later this year that could expand its current indication for flare treatment.
BI Prepares For Regulatory Filings After Spevigo Successfully Prevents GPP Flares
In Phase IIb trial
The German firm’s Spevigo seems set to dominate the generalized pustular psoriasis market after it reduced the risk of flares in the pivotal EFFISAYIL 2 trial, triggering label expansion plans less than a year after it was approved for flare treatment.
